Loading organizations...
Loading organizations...
Minimally invasive devices is a technology company.
Virtuoso Surgical develops a robotically controlled endoscopic surgical system designed to overcome the inherent limitations of traditional endoscopic tools. Its core product features two needle-sized robotic manipulators that extend from the tip of a rigid endoscope, enabling enhanced dexterity and precision during minimally invasive procedures. This innovative approach focuses on improving surgical access and operational control within confined anatomical spaces.
The company was founded in 2016 by Robert Webster, who serves as the primary inventor of the underlying technology. Webster’s insight stemmed from identifying the constraints faced by surgeons using conventional endoscopes, which lacked the necessary articulation and maneuverability for complex interventions. This realization spurred the creation of a system that integrates advanced robotics with existing endoscopic practices.
Surgical professionals performing a range of minimally invasive endoscopic procedures constitute the primary user base for Virtuoso Surgical's technology. The company's long-term vision is to radically improve the efficacy and scope of minimally invasive surgery, thereby facilitating more precise and less invasive treatments for patients globally. It aims to set new standards for robotic assistance in endoscopic environments.
Minimally invasive devices has raised $32.5M across 5 funding rounds.
Minimally invasive devices has raised $32.5M in total across 5 funding rounds.
Minimally invasive devices has raised $32.5M in total across 5 funding rounds.
Minimally invasive devices's investors include ARCH Venture Partners, Canaan Partners, Square 1 Bank, Charter Life Sciences, Radius Ventures, Brent Ahrens, Tony Shipley.
Minimally Invasive Devices, Inc. (MID), also associated with FloShield, Inc., develops the FloShield® family of products, innovative laparoscopic devices that maintain clear vision during minimally invasive surgeries by actively defogging lenses and shielding them from smoke and debris[1][2][3]. These products serve surgeons and medical institutions performing laparoscopic procedures, solving the critical problem of scope removal interruptions, which reduces procedure times and improves surgical efficiency[1][2][3]. With 11-50 employees, revenue between $1M-$5M, and $15.5M in total funding (including a $12.1M round), the company demonstrates steady growth in the medical device sector, headquartered in Columbus, Ohio[1][3].
Specific details on founders or exact founding year are not available in current sources, but MID emerged as a medical device innovator focused on laparoscopic challenges, creating the FloShield® line to address vision obstruction issues in surgeries[1][3]. Early traction likely stemmed from the need for reliable lens protection in high-definition procedures, leading to product evolution including FloShield Air and FloShield Plus, compatible with traditional and robotic laparoscopes[2]. The company's pivot to Vortex Barrier Technology marked a pivotal moment, enabling active defogging and debris prevention, with headquarters established at 1275 Kinnear Road, Columbus[1][3].
MID rides the wave of the expanding minimally invasive surgery devices market, valued at ~$20B in 2018 and projected to grow ~8% yearly through 2024, driven by demands for better patient outcomes, faster recovery, and tech integrations like advanced cameras and robotics[5]. Timing aligns with rising laparoscopic adoption amid robotics advancements from leaders like Intuitive Surgical and Medtronic, where clear vision is paramount[4]. Favorable market forces include regulatory pushes for less invasive procedures and IoT/sensor innovations enabling "smarter" tools; MID influences the ecosystem by specializing in vision tech, complementing giants and filling gaps in procedure optimization[4][5][6].
MID's focus on vision clarity positions it for growth as robotic surgery proliferates and minimally invasive tech incorporates AI, IoT, and real-time data for predictive care[5][6]. Next steps likely include expanding FloShield variants, international scaling, or partnerships with OEMs like Olympus amid market concentration by top players[4][6]. Evolving trends in sensors and blockchain for data handling could amplify its edge, potentially boosting influence in a maturing ecosystem—echoing its origin in solving a persistent surgical pain point for broader adoption.
Minimally invasive devices has raised $32.5M across 5 funding rounds. Most recently, it raised $14.0M Series C in November 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2015 | $14.0M Series C | ARCH Venture Partners, Canaan Partners | |
| Jul 2, 2015 | $5.0M Debt | Square 1 Bank | |
| Jun 1, 2013 | $3.0M Series B | ARCH Venture Partners, Canaan Partners, Canaan Partners, Charter Life Sciences, Radius Ventures | |
| Mar 1, 2013 | $9.0M Series B | Brent Ahrens | ARCH Venture Partners, Canaan Partners, Charter Life Sciences |
| Dec 28, 2010 | $1.5M Other Equity | Tony Shipley |